Traditional biomarkers for sepsis-induced coagulopathy have limited specificity and sensitivity, while emerging biomarkers reflecting endothelial dysfunction show promise but require further validation.
Do traditional and emerging biomarkers accurately diagnose sepsis-induced coagulopathy and disseminated intravascular coagulation in septic patients?
Individual biomarkers lack sufficient sensitivity and specificity for early diagnosis of sepsis-induced coagulopathy, necessitating the use of integrated scoring systems like the ISTH two-step approach.
Diagnosing coagulopathy in septic patients remains challenging in intensive care. Disseminated intravascular coagulation (DIC) indeed presents with complex pathophysiology, complicating timely diagnosis. Epidemiological data indicate a significant prevalence of DIC in septic patients, with mortality rates up to 60%. Despite advances, current biomarker-based diagnostic tools often fail to provide early and accurate detection. This review evaluates the utility and limitations of traditional and emerging biomarkers for diagnosing sepsis-induced coagulopathy (SIC) and DIC. We also assess the effectiveness of anticoagulant therapy guided by biomarker-based diagnostic criteria.
Curtiaud et al. (Wed,) conducted a review in Sepsis-induced coagulopathy (SIC) and disseminated intravascular coagulation (DIC). Biomarkers for sepsis-induced coagulopathy was evaluated. Traditional biomarkers for sepsis-induced coagulopathy have limited specificity and sensitivity, while emerging biomarkers reflecting endothelial dysfunction show promise but require further validation.